FINEARTS-HF trial shows finerenone benefits for heart failure with preserved ejection fraction

According to a study presented at ESC Congress 2024, the drug finerenone significantly reduces heart failure events and cardiovascular death among patients with heart failure and mildly reduced or preserved ejection fraction. The study provided the first definitive evidence that mineralocorticoid receptor antagonists can benefit these patients. The trial involved 6,001 randomised patients and showed positive results for finerenone, especially in those already receiving another therapy.